FDA approval of Alzheimer's drug 'a turning point'
Headline from WHEC Rochester
ROCHESTER, N.Y. — In a scientific breakthrough in the fight against Alzheimer’s disease, the Food and Drug Administration has given traditional approval to medication called Leqembi.It was given accelerated approval back in January — but after getting the full-fledged green light Thursday, Leqembi i…
WHEC Rochester's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
(CNN) — The US Food and Drug Administration is expected to decide on Thursday whether to grant traditional approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease.
WASHINGTON >> U.S. officials granted full approval to a closely watched Alzheimer’s drug today, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Leqembi is not a cure, but it is the first drug shown to slow the progression of Alzheimer's disease. It first received an accelerated approval from the FDA earlier this year.
By Meg Tirrell, Nadia Kounang and Tami Luhby, CNN (CNN) — The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease.
The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease.
The FDA granted traditional approval to Leqembi on Thursday afternoon, a drug that has been shown to slow cognitive decline in early-stage Alzheimer's patients.
(CNN) — The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course
Leqembi, a drug that can help treat adult patients with Alzheimer’s, was given traditional approval by the FDA on Thursday. It was first approved in January for clinical trials.
WASHINGTON — U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Medicare will cover much of the cost for patients in the early stages of the disease, but Leqembi has safety risks and can only modestly slow cognitive decline.
What You Need To Know The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer’s drug lecanamab, marked as Leqembi by drugmakers Eisai a...
WASHINGTON (AP) — U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin
